The International Union Against Cancer believes that one-third of cancers are preventable, one-third can be cured if diagnosed early, and one-third can be alleviated to help prolong patients’ life. Cancer control isRead More…
Immunotherapy with checkpoint inhibitors is more effective in cancer patients who have elevated numbers of specific types of immune cells inside their tumors, a study suggests. Patients with a favorable combination of immuneRead More…
The receptors, found in so-called elite controllers who don’t need medications to keep the virus in check, suggest a new path toward immunotherapy. Researchers trying to develop new treatments, or even aRead More…
Unlike the mechanism of action of traditional treatments, immunotherapy is uniquely characterized by its long-term response and survival in efficacy, unconventional delayed response and pseudo-progression in response mode, a new assessment endpointRead More…
“Two new studies use new models to identify genetic targets and test promising treatments for adrenal cancer. One patient was treated with the immunotherapy pembrolizumab and now more than a year afterRead More…
There is no doubt that this year marks the beginning of CAR-T therapy owing to the advent of two CAR-T therapies and the changes that these therapies have brought to the lives ofRead More…
Actemra/RoActemra® is the first FDA approved drug for treatment of serious or fatal cytokine release syndrome (CRS) caused by CAR-T therapy; CAR-T cell therapy is an immunotherapy used to treat certain typesRead More…
On August 24th, a reporter was informed from Prof. Guangmei Yan research group at Zhongshan University that this group of researchers identified and gained oncolytic virus M1 synergist with accurate treatment ofRead More…
Car-T for Autoimmune Disease An autoimmune disease is a pathological condition resulting from an abnormal immune response to tissues that can exist in the body, affecting up to 50 million Americans in termsRead More…
Chimeric antigen receptor (CAR) modified T cells (CAR-T) as a new field of adoptive immune cell therapy has become a hot spot in recent research. In 1989, Israeli scholar Gross et al.Read More…